Glass House Brands (GLAS) Total Non-Current Liabilities (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Total Non-Current Liabilities of $111.9 million for Q1 2026, little changed year-over-year from $111.8 million in Q1 2025, and up 5.08% quarter-over-quarter from $106.5 million in Q3 2025.
Glass House Brands (GLAS) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Total Non-Current Liabilities for 7 consecutive years, with $111.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities changed 0.09% year-over-year to $111.9 million; the TTM figure through Mar 2026 stood at $111.9 million (changed 0.09% YoY), while the FY2024 annual figure was $234000.0, down 1.68% from the prior year.
- Total Non-Current Liabilities climbed to $111.9 million in Q1 2026 per GLAS's latest filing, from $106.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $6314.3 billion in Q2 2022 and bottomed at -$19099.6 billion in Q2 2023.
- Historically, Total Non-Current Liabilities has averaged -$799.0 billion across 5 years, with a median of $112.9 million in 2025.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities surged 508.06% — and 2023, when it sank 402.48%.
- Glass House Brands' Total Non-Current Liabilities stood at $241373.0 in 2022, then dropped by 1.4% to $238000.0 in 2023, then fell by 1.68% to $234000.0 in 2024, then surged by 45396.15% to $106.5 million in 2025, then climbed by 5.08% to $111.9 million in 2026.
- Business Quant data shows GLAS's Total Non-Current Liabilities at $111.9 million in Q1 2026, $106.5 million in Q3 2025, and $114.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Glass House Brands | 825.81 Mn | 807.26 Mn | 15.77 Mn | 109.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 111.87 Mn |
| Sep 30, 2025 | 106.46 Mn |
| Jun 30, 2025 | 114.01 Mn |
| Mar 31, 2025 | 111.77 Mn |
| Dec 31, 2024 | 234,000.00 |
| Sep 30, 2024 | 142.81 Mn |
| Jun 30, 2024 | 167.07 Mn |
| Mar 31, 2024 | 160.87 Mn |
| Dec 31, 2023 | 238,000.00 |
| Sep 30, 2023 | 152.08 Mn |
| Jun 30, 2023 | -19,099.58 Bn |
| Mar 31, 2023 | 132.95 Mn |
| Dec 31, 2022 | 241,373.00 |
| Sep 30, 2022 | 160.98 Mn |
| Jun 30, 2022 | 6,314.33 Bn |
| Mar 31, 2022 | 65.28 Mn |
| Dec 31, 2021 | 104.20 Mn |
| Sep 30, 2021 | 26.47 Mn |
| Mar 31, 2021 | 479.73 Mn |
| Dec 31, 2020 | 456.33 Mn |